Dr. Charles Quinn, MD

NPI: 1962465864
Total Payments
$21,311
2021 Payments
$2,720
Companies
4
Transactions
12

Payment Breakdown by Category

Consulting$20,250 (95.0%)
Travel$778.14 (3.7%)
Food & Beverage$250.37 (1.2%)
Education$32.27 (0.2%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $20,250 6 95.0%
Travel and Lodging $778.14 2 3.7%
Food and Beverage $250.37 3 1.2%
Education $32.27 1 0.2%

Top Paying Companies

Company Total Records Latest Year
Celgene Corporation $14,042 7 $0 (2020)
Merck Sharp & Dohme Corporation $4,500 1 $0 (2018)
Novo Nordisk Inc $2,752 3 $0 (2021)
Novartis Pharmaceuticals Corporation $16.86 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2021 $2,720 2 Novo Nordisk Inc ($2,720)
2020 $3,032 2 Celgene Corporation ($3,000)
2019 $8,963 5 Celgene Corporation ($8,946)
2018 $6,596 3 Merck Sharp & Dohme Corporation ($4,500)

All Payment Transactions

12 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
04/16/2021 Novo Nordisk Inc Consulting Fee Cash or cash equivalent $1,360.00 General
04/15/2021 Novo Nordisk Inc Consulting Fee Cash or cash equivalent $1,360.00 General
08/21/2020 Celgene Corporation REBLOZYL (Biological) Consulting Fee Cash or cash equivalent $3,000.00 General
Category: Hematology
07/15/2020 Novo Nordisk Inc Education In-kind items and services $32.27 General
04/03/2019 Celgene Corporation Luspatercept (Drug) Consulting Fee Cash or cash equivalent $8,050.00 General
03/22/2019 Celgene Corporation Luspatercept (Drug) Travel and Lodging In-kind items and services $641.29 General
03/22/2019 Celgene Corporation Luspatercept (Drug) Travel and Lodging In-kind items and services $136.85 General
03/22/2019 Celgene Corporation Luspatercept (Drug) Food and Beverage In-kind items and services $117.74 General
03/01/2019 Novartis Pharmaceuticals Corporation Food and Beverage In-kind items and services $16.86 General
12/20/2018 Celgene Corporation Luspatercept (Drug) Consulting Fee Cash or cash equivalent $1,980.00 General
12/01/2018 Celgene Corporation Luspatercept (Drug) Food and Beverage In-kind items and services $115.77 General
09/06/2018 Merck Sharp & Dohme Corporation V114 (Biological) Consulting Fee Cash or cash equivalent $4,500.00 General
Category: VACCINE

About Dr. Charles Quinn, MD

Dr. Charles Quinn, MD is a Pediatric Hematology-Oncology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962465864.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Quinn, MD has received a total of $21,311 in payments from pharmaceutical and medical device companies, with $2,720 received in 2021. These payments were reported across 12 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($20,250).

Practice Information

  • Specialty Pediatric Hematology-Oncology
  • Location Cincinnati, OH
  • Active Since 04/11/2006
  • Last Updated 06/02/2010
  • Taxonomy Code 2080P0207X
  • Entity Type Individual
  • NPI Number 1962465864

Products in Payments

  • Luspatercept (Drug) $11,042
  • V114 (Biological) $4,500
  • REBLOZYL (Biological) $3,000

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Hematology-Oncology Doctors in Cincinnati